Regeneron Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Regeneron Pharmaceuticals, Inc.

Nov-19	EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications REGN GlobeNewswire
Nov-19	Libtayo (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation REGN GlobeNewswire
Nov-13	Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs REGN GlobeNewswire
Nov-08	Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet REGN GlobeNewswire
Nov-07	Dupixent (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review REGN GlobeNewswire
Nov-03	Regeneron Announces Investor Conference Presentations REGN GlobeNewswire
Oct-31	Dupixent (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award REGN GlobeNewswire
Oct-28	Regeneron Reports Third Quarter 2025 Financial and Operating Results REGN GlobeNewswire
Oct-17	Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation REGN GlobeNewswire
Oct-15	Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers REGN GlobeNewswire
Oct-12	DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss REGN GlobeNewswire
Oct-08	Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation REGN GlobeNewswire
Sep-30	Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 REGN GlobeNewswire
Sep-26	Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol REGN GlobeNewswire
Sep-22	Dupixent (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion REGN GlobeNewswire
Sep-19	Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks REGN GlobeNewswire
Sep-17	Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD REGN GlobeNewswire
Sep-17	Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation REGN GlobeNewswire
Sep-09	Libtayo (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer REGN GlobeNewswire
Sep-08	Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies REGN GlobeNewswire
Sep-04	Regeneron Announces Updated Presentation Time for Upcoming Investor Conference REGN GlobeNewswire
Aug-26	Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis REGN GlobeNewswire
Aug-20	EYLEA HD (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension REGN GlobeNewswire
Aug-07	Regeneron Announces Investor Conference Presentations REGN GlobeNewswire
Aug-01	Regeneron Reports Second Quarter 2025 Financial and Operating Results REGN GlobeNewswire
Jul-24	Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation REGN GlobeNewswire
Jul-02	Lynozyfic (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma REGN GlobeNewswire
Jun-26	Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 REGN GlobeNewswire
Jun-24	Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization REGN GlobeNewswire
Jun-20	Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) REGN GlobeNewswire
Jun-15	Dupixent (dupilumab) Demonstrated Superiority Over Xolair (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial REGN GlobeNewswire
Jun-07	Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color REGN GlobeNewswire
Jun-02	Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist REGN GlobeNewswire
Jun-02	Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass REGN GlobeNewswire
May-31	Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing REGN GlobeNewswire
May-30	Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials REGN GlobeNewswire
May-22	Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma REGN GlobeNewswire
May-19	Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness REGN GlobeNewswire
May-16	75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition REGN GlobeNewswire
May-15	Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments REGN GlobeNewswire
May-01	Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination REGN GlobeNewswire
May-01	Dupixent (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases REGN GlobeNewswire

Regeneron Pharmaceuticals, Inc.

Recent Articles by Regeneron Pharmaceuticals, Inc.

Upgrade your FINVIZ experience